Effects of captopril on renal function in patients with cirrhosis and ascites.
Blockade of angiotensin-converting enzyme has been variously reported to increase or to decrease sodium excretion in patients with cirrhosis and ascites. We administered captopril (50-150 mg) to 11 patients with cirrhosis and ascites to determine the effects on blood pressure, renal blood flow and sodium excretion. Plasma renin activity increased and mean blood pressure fell (by 14 mm Hg). Para-aminohippurate clearances increased from 321 +/- 53 to 559 +/- 83 ml/min (P less than 0.005), but inulin clearances were minimally altered (73 +/- 8 to 76 +/- 7 ml/min), suggesting preferential dilation of glomerular efferent arterioles. Despite unchanged glomerular delivery of sodium, urinary sodium excretion fell in all subjects (from 2.70 +/- 1.00 to 0.48 +/- 0.21 mEq/h), urinary volume was reduced (377 +/- 55 to 182 +/- 42 ml/h, P less than 0.005), and the natriuretic effect of furosemide was blunted. The antinatriuretic effect of captopril may be mediated by reduced angiotensin II-mediated sodium excretion, by decreased prostaglandin production, and/or by indirect effects of reduced blood pressure. Captopril impairs rather than promotes sodium excretion.
Daskalopoulos
G
G
Pinzani
M
M
Murray
N
N
Hirschberg
R
R
Zipser
R D
RD
D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000502:physiology*; D001201:Ascites / Q000503:physiopathology; D001794:Blood Pressure; D002216:Captopril / Q000008:administration & dosage; D004232:Diuretics / Q000008:administration & dosage; D004347:Drug Interactions; D006439:Hemodynamics; D006801:Humans; D007668:Kidney / Q000098:blood supply / Q000503:physiopathology; D008104:Liver Cirrhosis, Alcoholic / Q000503:physiopathology*; D008875:Middle Aged; D009318:Natriuresis
D004232:Diuretics; D000804:Angiotensin II; D002216:Captopril